Alexium Goes Full Scale with US Sales

|

Published 14-SEP-2015 11:41 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

ASX-listed chemical company Alexium International (ASX:AJX) has bagged a full production run order for its Alexiflam product of 1.5 tonnes, and says it could be a sign of things to come.

Its product is used in the ‘ticking’ of mattresses, the final component of mattresses used to encase everything in the mattress while protecting internal materials. In this case, the Alexiflam product makes the mattress flame retardant.

In recent times AJX has been working closely with an unnamed major customer in the US on scaling up early tests with the material to full production.

It told the market this morning that the goal had been reached, with a full production run of the client’s mattresses coated with Alexiflam now bound for stores.

The order is for 1.5 tonnnes of Alexiflam, and AJX said it expects similar-sized orders to come in every month, giving the company regular income.

Crucially, AJX said the full-scale purchase order means it has been just four months from trial work to purchase order.

Last month it told shareholders that an initial order from the client would be worth $US200,000 ($A271,275) to $300,000 per month, with the revenue to start rolling in the third quarter.

It is unclear whether the ongoing orders will be within this range, or higher.

The client, however, is currently experimenting with Alexiflam in other products – possibly pointing to increased sources of revenue.

Last month’s news sent shares in AJX through the $1 mark, and while the shares have pulled back since then, it is currently up over 3.3% to 92.5c in early trading.

Last week it announced that Rhode Island-based supplier to the US military, Murdock Webbing, had agreed to use AJX’s product in stretch webbing used in flexible straps for goggles.

The product deal gives Alexium an entry into a global market which is worth a total of $3.2 billion.

While the initial deal covers goggles, Alexium said there was scope to increase the deal to other products such as backpacks, parachutes, field vests, duffle bags, uniform accessories, belts, and tents.

It said Murdock products with the AJX fire retardant finish should be available from the first quarter next year.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X